MX378012B - Compuestos de alquinil dihidroquinolina sulfonamida. - Google Patents

Compuestos de alquinil dihidroquinolina sulfonamida.

Info

Publication number
MX378012B
MX378012B MX2018007511A MX2018007511A MX378012B MX 378012 B MX378012 B MX 378012B MX 2018007511 A MX2018007511 A MX 2018007511A MX 2018007511 A MX2018007511 A MX 2018007511A MX 378012 B MX378012 B MX 378012B
Authority
MX
Mexico
Prior art keywords
dihydroquinoline
alkynyl
compounds
sulfonamide compounds
present
Prior art date
Application number
MX2018007511A
Other languages
English (en)
Other versions
MX2018007511A (es
Inventor
Karina R Vaida
Matthew Weiss
Thomas Dineen
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2018007511A publication Critical patent/MX2018007511A/es
Publication of MX378012B publication Critical patent/MX378012B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47042-Quinolinones, e.g. carbostyril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40Benzopyrazines
    • C07D241/44Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona compuestos de la Fórmula I, (ver Fórmula) y sal farmacéuticamente aceptables de los mismos que son inhibidores de canales de sodio abiertos por voltaje, en particular Nav1.7. Los compuestos son útiles para el tratamiento de enfermedades asociadas con actividad de canales de sodio tal como trastornos de dolor, tos, y comezón. También se proporcionan composiciones farmacéuticas que contienen compuestos de la presente invención.
MX2018007511A 2015-12-18 2016-12-19 Compuestos de alquinil dihidroquinolina sulfonamida. MX378012B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562269533P 2015-12-18 2015-12-18
PCT/US2016/067622 WO2017106872A1 (en) 2015-12-18 2016-12-19 Alkynyl dihydroquinoline sulfonamide compounds

Publications (2)

Publication Number Publication Date
MX2018007511A MX2018007511A (es) 2018-09-18
MX378012B true MX378012B (es) 2025-03-10

Family

ID=57758770

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018007511A MX378012B (es) 2015-12-18 2016-12-19 Compuestos de alquinil dihidroquinolina sulfonamida.

Country Status (8)

Country Link
US (1) US10729684B2 (es)
EP (1) EP3390393A1 (es)
JP (1) JP6985271B2 (es)
AU (1) AU2016369653B2 (es)
CA (1) CA3008485C (es)
MA (1) MA44066A (es)
MX (1) MX378012B (es)
WO (1) WO2017106872A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022515630A (ja) * 2018-12-26 2022-02-21 ラクオリア創薬株式会社 Nav1.7およびNav1.8遮断薬としての複素環誘導体
US20230090372A1 (en) * 2019-12-11 2023-03-23 Duke University Small molecule inhibitors of voltage-gated sodium channel 1.7 and methods of using same
JP7739051B2 (ja) 2020-06-10 2025-09-16 アムジエン・インコーポレーテツド シクロブチルジヒドロキノリンスルホンアミド化合物
JP2021195367A (ja) * 2020-06-10 2021-12-27 アムジエン・インコーポレーテツド シクロプロピルジヒドロキノリンスルホンアミド化合物
EP4595965A3 (en) * 2020-06-10 2025-08-13 Amgen Inc. Heteroalkyl dihydroquinoline sulfonamide compounds
CN117677608A (zh) * 2021-08-12 2024-03-08 浙江同源康医药股份有限公司 多环类化合物及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
EP2350091B1 (en) 2008-10-17 2015-06-03 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
US9346798B2 (en) * 2012-02-13 2016-05-24 Amgen Inc. Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors
US9051311B2 (en) 2012-03-09 2015-06-09 Amgen Inc. Sulfamide sodium channel inhibitors
US9212182B2 (en) * 2013-06-12 2015-12-15 Amgen Inc. Bicyclic sulfonamide compounds as sodium channel inhibitors

Also Published As

Publication number Publication date
US20180369226A1 (en) 2018-12-27
CA3008485A1 (en) 2017-06-22
WO2017106872A1 (en) 2017-06-22
MX2018007511A (es) 2018-09-18
JP6985271B2 (ja) 2021-12-22
AU2016369653B2 (en) 2021-02-04
MA44066A (fr) 2018-10-24
EP3390393A1 (en) 2018-10-24
US10729684B2 (en) 2020-08-04
AU2016369653A1 (en) 2018-07-05
CA3008485C (en) 2023-08-01
JP2018537505A (ja) 2018-12-20

Similar Documents

Publication Publication Date Title
UY35612A (es) Compuestos de sulfonamida bicíclicos como inhibidores de los canales de sodio
NI201900070A (es) Compuestos heterocíclicos como inmunomoduladores
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
MX379155B (es) Compuestos que inhiben la proteína mcl-1.
MX2018007774A (es) Compuestos heterociclicos como inmunomoduladores.
JOP20190229A1 (ar) مركبات تثبط بروتين mcl-1
CO2017009614A2 (es) Compuestos bicíclicos de sulfonamida cetona
CO2018011064A2 (es) Inhibidores de bromodominios
SA518391624B1 (ar) Ror- منظمات جاما
MX378012B (es) Compuestos de alquinil dihidroquinolina sulfonamida.
MX383856B (es) Compuestos y composiciones para inhibir la actividad de shp2.
MX2015009602A (es) Piridona amidas como moduladores de canales de sodio.
MX359882B (es) Amidas como moduladores de canales de sodio.
UY35273A (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn
CO2018007436A2 (es) Compuestos de dihidroquinolinsulfonamida de alquilo
PH12019502150A1 (en) Compounds and methods for the treatment of parasitic diseases
CL2017002957A1 (es) Benzamidas sustituidas y métodos para utilizarlas
MX382175B (es) Composiciones de profármaco de monometilfumarato
JOP20190053A1 (ar) مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
BR112018073419A2 (pt) combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
CL2020002398A1 (es) Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd")